Subscribe to RSS
DOI: 10.1055/s-2008-1074380
Nationwide Study on Moxifloxacin susceptibility among pneumococcal isolates from invasive disease in Germany
Background: In the last two decades, the worldwide increase in antibiotioc resistance in Streptococcus pneumoniae has developed into a serious problem.
Method: In this study 679 Streptococcus pneumoniae isolates, collected in Germany in the year 2006 were examined. Minimal inhibitory concentration (MIC) testing was performed using the broth microdilution method as recommended by the Clinical Laboratory Standards Institute. The pneumococcal strains were isolated from blood (n=568, 83,7%), Cerebrospinal fluid (CSF; n=86; 12,7%), broncho-alveolar lavage (n=12; 1,8%) und pleural fluid (n=13; 1,9%).
Results: MIC-values of moxifloxacin towards pneumococci were between ≤0,03 und 0,5µg/ml, independent of β-lactam or macrolide susceptibility. All isolates were susceptible towards moxifloxacin. A rate of macrolide resistant isolates was obeserved. The results of the antibiotic susceptibility testing are summarized in the table.
Conclusion: Our data show that moxifloxacin is a promising therapeutic option for the treatment of pneumococcal infections, including those which are caused by penicillin- or macrolide-resistant strains.
Table 1: Susceptibility of S.pneumoniae towards Moxifloxacin
|
|
Moxifloxacin |
Penicillin G |
Clarithromycin |
Clindamycin |
Cefotaxime |
|
MIC 50 |
0,12 |
≤0,015 |
≤0,12 |
≤0,12 |
0,03 |
|
MIC 90 |
0,25 |
≤0,016 |
8 |
≤0,13 |
0,03 |
|
% intermediate |
0 |
3,7 |
0 |
n=1 |
1,2 |
|
% resistant |
0 |
1,5 |
19,3 |
4,6 |
0,4 |
Bundesweite Studie zur Antibiotikaempfindlichkeit von Moxifloxacin bei Pneumokokken-Isolaten von invasiven Erkrankungen in Deutschland